Physician profile
Nitin K Gupta
NPI 1013113364
$1,071,299.92
in general payments reported to CMS, 2019-2025
43 companies · $264K in 2025
The $264K reported for 2025 was more than what 99% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $155K · 2020: $68K · 2021: $93K · 2022: $161K · 2023: $164K · 2024: $166K · 2025: $264K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $533K · Travel and Lodging: $49K · Food and Beverage: $12K · Education: $163.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $532,523.00 |
| Travel and Lodging | $49,176.94 |
| Food and Beverage | $12,129.10 |
| Education | $162.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $513,943.93 | 2019-2025 | |
| Janssen Biotech, INC. | $217,082.14 | 2019-2025 | Tremfya, Stelara |
| Janssen Scientific Affairs, LLC | $125,186.31 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $111,458.73 | 2021-2023 | Zeposia |
| Lilly USA, LLC | $52,380.01 | 2024-2025 | Omvoh |
| Pfizer INC. | $47,426.04 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,190.39 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Celgene Corporation | $491.84 | 2021-2024 | Zeposia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $480.52 | 2019-2024 | Xifaxan, Plenvu, Trulance |
| Merck Sharp & Dohme LLC | $224.93 | 2019-2023 | Dificid, Zinplava |
| Daiichi Sankyo INC. | $188.95 | 2021-2025 | Injectafer |
| Celltrion USA INC. | $168.11 | 2024-2025 | Vegzelma, Zymfentra |
| Ferring Pharmaceuticals INC. | $138.19 | 2019-2024 | Rebyota |
| Sandoz INC. | $118.91 | 2024-2025 | Hyrimoz |
| Boston Scientific Corporation | $102.94 | 2025 | Cre Pro, Compliance Endokit |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $72.59 | 2019 | |
| Aimmune Therapeutics, INC. | $69.10 | 2023-2024 | |
| Nestle Healthcare Nutrition INC. | $63.70 | 2020-2022 | |
| Ironwood Pharmaceuticals, INC | $55.26 | 2019-2022 | |
| Genzyme Corporation | $41.37 | 2022 | |
| Madrigal Pharmaceuticals | $36.05 | 2025 | Rezdiffra |
| Sanofi-Aventis U.S. LLC | $35.96 | 2023 | |
| Organon LLC | $34.96 | 2022-2023 | Renflexis, Hadlima |
| Medtronic, INC. | $32.00 | 2024 | Interstim |
| Ucb, INC. | $29.94 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $29.67 | 2022 | |
| Biocon Biologics INC | $23.66 | 2025 | Yesintek |
| Phathom Pharmaceuticals, INC. | $23.27 | 2024 | Voquezna |
| Vivus LLC | $21.61 | 2025 | Pancreaze |
| Braintree Laboratories, INC. | $20.84 | 2022 | |
| Mylan Institutional INC. | $20.53 | 2023 | Hulio |
| Ardelyx, INC. | $18.42 | 2024 | Ibsrela |
| Ipsen Biopharmaceuticals, INC | $17.39 | 2024 | Bylvay |
| Novo Nordisk INC | $16.77 | 2025 | Wegovy |
| Intra-Sana Laboratories | $15.19 | 2022 | |
| Lumendi LLC | $14.90 | 2021 | |
| Amgen INC. | $14.32 | 2023 | |
| Janssen Pharmaceuticals, INC | $10.48 | 2025 |
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nitin Gupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.